ISSN 2398-2942      

Oclacitinib

icanis

Synonym(s): Apoquel®.


Introduction

Name

  • Oclacitinib, Apoquel®.

Class of drug

  • Immunosuppressant.
  • Agents for dermatitis, excluding corticosteroids.
  • Synthetic Janus kinase (JAK) inhibitor.

Description

Chemical name

  • N-methyl-1-[4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl] methanesulfonamide.

Molecular formula

  • C19H27N5O6S.

Molecular weight

  • 453.51.

Physical properties

  • Film-coated tablets containing oclacitinib maleate.
  • White to off-white, oblong shaped film-coated tablets with a score-line on both sides and marked with the letters "AQ" and "S", "M" or "L" on both sides, which refer to the different strengths of tablets: "S" 3.6 mg, "M" 5.4 mg, and "L" 16 mg tablets.
  • The tablets can be divided into equal halves.

Storage requirements

  • Shelf life as packaged for sale: 2 years.
  • Store below 25 °C.
  • Any remaining half tablet should be placed back in the opened blister and stored in the original cardboard carton.
  • Any remaining half tablets should be discarded after 3 days.

Uses

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Indications

Administration

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Interactions

with other drugs

  • Adequate serological response to vaccination with modified live canine parvovirus (CPV) and canine distemper virus (CDV) in puppies administered oclacitinib at 1.8 mg/kg twice daily for 84 days.
  • Reduced serological response to vaccination with modified live canine parainfluenza virus (CPi) and inactivated rabies virus in puppies administered oclacitinib at 1.8 mg/kg twice daily for 84 days compared to untreated controls. The clinical relevance of these observed effects for vaccination of dogs on oclacitanib treatment is unclear.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to obtain ten tokens to view any ten Vetlexicon articles, images, sounds or videos, or Login

Further Reading

Publications

Refereed papers

  • Recent references from VetMedResource and PubMed.
  • Collard W T, Hummel B D, Fielder A F, King V L, Boucher J F, Mullins M A, Malpas P B, Stegemann M R (2014) The pharmacokinetics of oclacitinib maleate, a Janus kinase inhibitor, in the dog. J Vet Pharmacol Ther 37 (3), 279-285 PubMed.
  • Gonzales A J, Bowman J W, Fici G J, Zhang M, Mann D W, Mitton-Fry M (2014) Oclacitinib (APOQUEL(®) ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 37(4), 317-324 PubMed.
  • Cosgrove S B, Wren J A, Cleaver D M, Martin D D, Walsh K F, Harfst J A, Follis S L, King V L, Boucher J F, Stegemann M R (2013) Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 24(5), 479-e114 PubMed.
  • Cosgrove S B, Wren J A, Cleaver D M, Walsh K F, Follis S I, King V I, Tena J K, Stegemann M R (2013) A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Vet Dermatol 24(6), pp. 587-597 PubMed.

Other sources of information

MEMBER BENEFIT

Can’t find what you’re looking for?

We have an ever growing content library on Vetlexicon so if you ever find we haven't covered something that you need please fill in the form below and let us know!

 
 
 
 

To show you are not a Bot please can you enter the number showing adjacent to this field

 Security code